Categories
Anticancer Drugs Oncology Pexidartinib Pharmacology Physiotherapy

Pexidartinib and Patients with Renal Impairment

In this article we will discuss Pexidartinib and Patients with Renal Impairment

In this article, we will discuss Pexidartinib and Patients with Renal Impairment. So, let’s get started.

Pexidartinib and Patients with Renal Impairment

Mild (CLcr 60 to 89 mL/min), moderate (CLcr 30 to 59 mL/min) and severe (CLcr 15 to
29 mL/min) renal impairment increased pexidartinib exposure (AUC) by approximately 30%, relative to that in patients with normal renal function (CLcr ≥90 mL/min).

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.